Aurobindo Pharma’s Board of Directors has approved an interim dividend of 700%, equivalent to ₹7.00 per equity share, with a record date of November 11, 2026. The board also approved a scheme of amalgamation for the merger of its wholly owned subsidiaries, Auroactive Pharma Private Limited and Apitoria Pharma Private Limited. Additionally, the transfer of ownership of Auro Pharma LLC, Russia, was approved. These decisions, made on November 4, 2026, reflect the company’s strategic corporate actions and commitment to shareholder returns.
Interim Dividend and Amalgamation Approved
On November 4, 2026, the Board of Directors of Aurobindo Pharma Limited convened a meeting where several key strategic decisions were made. The most significant among these was the approval of an interim dividend of 700%, amounting to ₹7.00 per equity share of Re.1/- each. The company has set November 11, 2026, as the record date for this dividend payment, which is expected to be disbursed on or before November 20, 2026.
Strategic Corporate Restructuring
In a move towards corporate restructuring, the Board has also given its nod to a proposal for filing a Scheme of Amalgamation. This scheme pertains to the merger of two wholly owned subsidiaries: Auroactive Pharma Private Limited with Apitoria Pharma Private Limited. The proposal has been approved by the respective companies’ boards and will be filed with the Hon’ble National Company Law Tribunal (NCLT), Hyderabad. Furthermore, the transfer of ownership of Auro Pharma LLC, Russia, from Auroactive Pharma Private Limited to Auropharm Overseas Limited, both wholly owned subsidiaries, has also been approved by their respective boards.
Financial Results and Auditor Review
The Board also considered and approved the standalone and consolidated Unaudited Financial Results for the second quarter and half-year ended September 30, 2026. These results, along with the Limited Review Reports issued by the Statutory Auditors, have been enclosed with the announcement. The auditors have provided an unmodified conclusion on the review of these financial results.
Director Re-appointment
In another significant decision, based on the recommendation of the Nomination and Remuneration/Compensation Committee, the Board has approved the re-appointment of Mr. Mangalam Ramasubramanian Kumar as a Director (Non-executive and Independent). This re-appointment is for a second term of 5 years, effective from April 1, 2027, and is subject to the approval of the Members through a Postal Ballot. His current term as an Independent Director concludes on March 31, 2027.
Source: BSE
